French specialty vaccine company Valneva and U.S. drugmaker Pfizer reported positive results from the companies’ Phase II study on a vaccine candidate for Lyme disease.
CanSino Biologics Inc.’s single-dose Covid-19 vaccine – given at a lower dosage than that for adults – is safe and triggers an immune response in children aged 6-17, results from a small trial showed.
French vaccine maker Valneva is expanding trials of a Covid-19 vaccine candidate called VLA2001, and remains in talks with the European Commission over a potential contract, the company said on Sept. 23.
Valneva SE commenced rolling submission for initial approval of the company’s COVID-19 vaccine candidate VLA2001 with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
Valneva SE announced the initiation of a further Phase 3 trial (VLA2001-304) for the company’s inactivated, adjuvanted Covid-19 vaccine candidate VLA2001.
Antibody levels in people inoculated with CanSino Biologics’ (CanSinoBIO) single-dose Covid-19 vaccine fell by some 30 percent after six months, however a booster shot could offer a significant lift, a senior executive said on Aug. 5.
An inhalation version of CanSino Biologics’ Covid-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said on June 2.
China’s CanSino Biologics will initiate clinical trials of an experimental Covid-19 vaccine that is inhaled, instead of injected.
China’s CanSino Biologics Inc. said the efficacy rate for the company’s single-dose Covid-19 vaccine may fall over time although it should still have a rate of 50 percent or more five to six months after inoculation.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
